Welcome to our dedicated page for Processa Pharmaceuticals Common news (Ticker: PCSA), a resource for investors and traders seeking the latest updates and insights on Processa Pharmaceuticals Common stock.
Processa Pharmaceuticals, Inc. (symbol: PCSA) is a clinical-stage biopharmaceutical company, founded in October 2017 and headquartered in Hanover, Maryland. The company's mission is to develop products that can significantly improve the survival and quality of life for patients with high unmet medical needs, particularly in the field of oncology.
Processa Pharmaceuticals specializes in the development of Next Generation Chemotherapy (NGC) oncology drug products using a unique 'regulatory science' approach. The company's primary focus is to advance its pipeline of proprietary small molecule oncology drugs. These NGC products are new chemical entities designed to alter the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites, while preserving the original mechanisms of action that kill cancer cells.
The company's current pipeline includes three promising NGC treatments:
- NGC-Capecitabine (NGC-Cap): This therapy involves Capecitabine administered with PCS6422, aiming to enhance efficacy and reduce side effects.
- PCS3117 (NGC-Gemcitabine or NGC-Gem): A novel formulation intended to improve the therapeutic profile of Gemcitabine.
- PCS11T (NGC-Irinotecan or NGC-Iri): Another innovative treatment designed to optimize the benefits of Irinotecan.
Processa Pharmaceuticals is committed to leveraging its expertise in regulatory science to bring these next-generation treatments to market. The company's strategic partnerships and ongoing clinical trials play a crucial role in advancing its mission and providing hope to patients battling cancer. For the latest updates and more information, investors can contact Patrick Lin at plin@processapharma.com.
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) has announced significant advancements in its clinical trials and financial results for the year ending December 31, 2022. The company focuses on the development of Next Generation Chemotherapy drugs, particularly the Next Generation Capecitabine, which aims to reduce side effects experienced by patients on standard capecitabine. A successful Phase 2A trial for PCS12852 also opens avenues for out-licensing opportunities. Financially, Processa reported a net loss of $27.4 million and a cash balance of $6.5 million as of year-end. Funds raised post-year-end are expected to support operations into Q3 2024.
Processa Pharmaceuticals (Nasdaq: PCSA) has announced a conference call scheduled for March 30, 2023, at 4:30 p.m. EST. The call will cover the company’s 2022 results and updates on its clinical pipeline for 2023. Interested participants can join via teleconference or live webcast. The call aims to discuss the development of Next Generation Chemotherapy drugs aimed at improving the safety and efficacy profiles compared to existing treatments. Processa is currently developing three oncology treatments, including PCS6422 and PCS3117, targeting various cancers.
FAQ
What is the current stock price of Processa Pharmaceuticals Common (PCSA)?
What is the market cap of Processa Pharmaceuticals Common (PCSA)?
What is Processa Pharmaceuticals, Inc.?
When was Processa Pharmaceuticals founded?
Where is Processa Pharmaceuticals headquartered?
What is the mission of Processa Pharmaceuticals?
What does NGC stand for?
What are the main products in Processa Pharmaceuticals' pipeline?
What is the unique approach of Processa Pharmaceuticals?
How can investors get more information about Processa Pharmaceuticals?
What recent achievements has Processa Pharmaceuticals made?
Does Processa Pharmaceuticals have any partnerships?
